Liang L Qiao

US Patent:

7205126, Apr 17, 2007

Filed:

Feb 17, 2005

Appl. No.:

11/060034

Inventors:

Liang Qiao - Maywood IL, US
Wei Shi - Maywood IL, US
Yujun Huang - Maywood IL, US
Jianzhong Liu - Maywood IL, US

Assignee:

Loyola University Chicago - Maywood IL

International Classification:

C12P 21/06

US Classification:

435 691, 4353201, 4352351

Abstract:

The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

US Patent:

8129144, Mar 6, 2012

Filed:

Apr 9, 2007

Appl. No.:

11/784626

Inventors:

Liang Qiao - Maywood IL, US
Wei Shi - Maywood IL, US
Yujun Huang - Maywood IL, US
Jianzhong Liu - Maywood IL, US

Assignee:

Loyola University Chicago - Maywood IL

International Classification:

C12P 21/06

US Classification:

435 691, 4353201

Abstract:

The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

US Patent:

20030129728, Jul 10, 2003

Filed:

Nov 14, 2002

Appl. No.:

10/294087

Inventors:

Liang Qiao - Maywood IL, US
Wei Shi - Maywood IL, US
Yujun Huang - Maywood IL, US
Jianzhong Liu - Maywood IL, US

International Classification:

C12N007/00

US Classification:

435/235100

Abstract:

The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It characterizes that: the HPV or BPV pseudo-virus made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), reassembled into pseudo-virus (VLPs with plasmids inside). The pseudo-virus can be orally given, entering mucosa and systemic lymphoid tissues of human body, activate immune system and serve as treating and preventing agent. The pseudo-virus can induce stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in human body.

US Patent:

20120164173, Jun 28, 2012

Filed:

Mar 6, 2012

Appl. No.:

13/413386

Inventors:

Liang Qiao - Maywood IL, US
Wei Shi - Maywood IL, US
Yujun Huang - Maywood IL, US
Jianzhong Liu - Maywood IL, US

International Classification:

A61K 39/12
A61K 39/00
A61P 31/04
A61P 37/04
A61P 31/00
A61P 31/12
A61K 48/00
A61K 39/02

US Classification:

4242041, 514 44 R, 4241841, 4242341

Abstract:

The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

US Patent:

20230065376, Mar 2, 2023

Filed:

Feb 4, 2021

Appl. No.:

17/797662

Inventors:

- New York NY, US
- Maywood, IL
Liang QIAO - Maywood IL, US
Frank GAMBINO - Maywood IL, US

International Classification:

A61K 39/12
A61P 31/14

Abstract:

Provided herein are immunogenic compositions for the prevention of Zika virus infections. Disclosed herein are immunogenic compositions comprising an expression vector and a nucleotide sequence disposed therein, wherein the nucleotide sequence comprises: a nucleotide sequence encoding a Zika virus NS3 protein. Further disclosed herein are methods for preventing a Zika virus infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of an immunogenic composition of the present disclosure to the subject.